Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 4 member G (CLEC4G), also known as LSECtin, is a glycan-binding receptor belonging to the C-type lectin family and is expressed on liver and lymph node sinusoidal endothelial cells[1][8]. It binds specific carbohydrates including mannose, N-acetylglucosamine (GlcNAc), and fucose in a calcium-dependent manner[1][4]. CLEC4G plays a functional role in the immune response, particularly in the recognition and clearance of glycosylated pathogens, and helps regulate T cell-mediated immunity[5][8]. It is localized to the cell membrane, expressed primarily in the liver and lymph nodes, and is a type II transmembrane protein with documented glycosylation[1][4][8]. CLEC4G has been implicated as a negative immune marker and may serve as a potential therapeutic target in infectious and tumoral contexts, although no approved drugs specifically target this molecule to date[3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 4 member G (CLEC4G).